Technology | December 10, 2009

Nonlinear Algorithm Used to Identify Youth at Risk of Sudden Cardiac Death

December 11, 2009 – A new nonlinear algorithm has been selected for a month-long April 2010 noninvasive cardiac screening of teenagers in danger of sudden cardiac death in south east London. Vicor Technologies Inc. said its PD2i nonlinear algorithm will be used along with ECG and echocardiogram to identify those at risk.

Dr. Sanjay Sharma, consultant cardiologist of cardiac risk in the young, is spearheading the screening initiative that will offer free cardiac screenings to 14 year olds living in South East London. Studies show 14 is the earliest post-puberty age for which proactive screening is considered viable. The ultimate goal of the initiative is to develop a prototype for a national screening program for young sudden cardiac death. About 600 young people are struck down by sudden cardiac death annually in the U.K.

The company said its algorithm gives consistently accurate results in risk stratifying adults at for sudden cardiac death.

Dr. Sharma was recently-appointed professor of the newly-created Inherited Cardiovascular Disease and Sports Cardiology Centre at St. George’s Healthcare NHS Trust. He will begin his tenure in February 2010. The Centre is the world’s first specialist, multidisciplinary facility dedicated to providing services to populations affected by or at risk for (including families and athletes) young (14-35) sudden cardiac death. St. George’s is one of England’s largest teaching hospitals and the first hospital in the United Kingdom to develop a specialist clinic for young sudden cardiac death.

Vicor is a development-stage biotechnology company creating noninvasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i). The PD2i nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials to predict future pathological events.

Vicor currently has three products employing the PD2i nonlinear algorithm. The PD2i Analyzer, which has FDA 510(k) marketing clearance, measures heart rate variability. The physicians performing diagnostic tests with the PD2i Analyzer are able to receive reimbursement under existing CPT codes. The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research for risk stratification of combat and civilian trauma victims. The PD2i CA (Cardiac Analyzer) is in multiple clinical trials and identifies patients at risk of sudden cardiac death.

For more information:

Related Content

HeartSciences MyoVista ECG Device Shows Promise in Detecting Abnormal Cardiac Function
News | ECG | April 27, 2018
HeartSciences announced the results of a clinical study of its electrocardiography device that applies continuous...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG | December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG | August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG | August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG | July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG | January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG | October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG | November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG | October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG | September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
Overlay Init